Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 15, 2016
Grant Date -
Jun 18, 2015
app pub date -
Jan 28, 2013
filing date -
Jan 27, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41−), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully